来自自然产品的酶及其衍生抑制剂
Takudzwa Chipeperengo Chiwoneso1, Yajing Luo1, Yifan Xu1
1State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198 China.
Bioorganic chemistry
|February 5, 2025
概括
蛋白激酶抑制剂 (PKI) 在癌症治疗中至关重要,但面临毒性和耐药性等挑战. 本综述分析了天然产品衍生的PKI,以指导开发更安全,更有效的癌症疗法.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药用化学 医学化学
背景情况:
- 蛋白激酶失调是许多癌症的关键特征,其机制仍在研究中.
- 来自自然产品的早期蛋白激酶抑制剂 (PKIs) 具有高细胞毒性,而合成药物则面临药物耐药性.
- 了解激酶功能对于开发向癌症疗法至关重要.
研究的目的:
- 审查了解蛋白激酶在癌症中的作用的进展.
- 分析FDA批准的自然产品衍生激酶抑制剂 (NPDKI) 和失败的自然产品衍生激酶抑制剂.
- 推进药物化学策略,以开发更安全,更有效的PKI.
主要方法:
- 关于癌症中蛋白激酶功能和失调的文献综述.
- 对FDA批准的NPDKI的合成和修改进行分析.
- 检查未通过临床试验的NPDKI.
主要成果:
- 鉴定了目前PKI发展中的挑战,包括毒性和耐药性.
- 突出了NPDKI开发中的成功和失败的策略.
- 提供了对影响PKI有效性和安全性的化学修饰的见解.
结论:
- 对NPDKI的进一步研究可以改善癌症治疗结果.
- 药物化学方法应专注于提高疗效,同时最大限度地降低毒性.
- 了解NPDKI历史上的成功和失败是未来药物设计的关键.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Protein Kinases and Phosphatases
13.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
Enzyme Inhibition
77.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.8K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K


